ANZUP Mini ASM 2021
UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Related Articles
Advances in Staging and Personalized Radiation Therapy for High-Risk Localized Prostate Cancer – Leslie Ballas
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Leslie…
Managing Nonmetastatic Castration-Resistant Prostate Cancer – Zachary Reardon
Zach Klaassen and Zach Reardon delve into the nuances of managing nonmetastatic castration-resistant prostate cancer (nmCRPC) in clinical practice. Dr. Reardon discusses the evolving landscape…
The Best of ASCO 2024 in Advanced Bladder Cancer – Shilpa Gupta
Ashish Kamat interviews Shilpa Gupta about the best of ASCO 2024 in advanced bladder cancer. Dr. Gupta discusses three abstracts: the CheckMate-901 trial’s analysis of…
Tumor Suppressor Gene Signature Predicts Early Progression in mHSPC – Marta Garcia de Herreros
Neeraj Agarwal interviews Marta Garcia de Herreros about presentation on tumor suppressor gene (TSG) signatures in metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Garcia de Herreros…
PATCH Trial Evaluates Transdermal Estradiol in Non-Metastatic Prostate Cancer – Duncan Gilbert
Duncan Gilbert discusses the PATCH trial, comparing transdermal estradiol with LHRH agonists for androgen suppression in non-metastatic prostate cancer. Dr. Gilbert discusses the trial design,…
Radium-223 Plus Enzalutamide Improves Survival in mCRPC: PEACE-3 Trial Results, Journal Club – Rashid Sayyid & Zachary Klaassen
Rashid Sayyid and Zachary Klaassen discuss the resurgence of radium-223 in treating metastatic castration-resistant prostate cancer (mCRPC), focusing on the PEACE-3 trial results. The conversation…
Utilizing the Decipher mRNA Score for Risk Stratification in mHSPC – David Morris and Ashley Ross
Ashley Ross and David Morris discuss the use of the Decipher Genomic Classifier in metastatic hormone-sensitive prostate cancer (mHSPC). They explore how Decipher can help…
Understanding KEYNOTE-564: Pembrolizumab’s Role and Post-Adjuvant Therapy for RCC Patients – Karl Semaan & Talal El Zarif
Zach Klaassen engages with Talal El Zarif and Karl Semaan to discuss the results of the KEYNOTE-564 trial on adjuvant immunotherapy for renal cell carcinoma…
EMBARK Trial: Age-Stratified Analysis of Enzalutamide in High-Risk Biochemically Recurrent Prostate Cancer – Neal Shore
Zach Klaassen interviews Neal Shore about the EMBARK trial’s post hoc analysis by age. The study examines the efficacy of enzalutamide alone or combined with…
Advanced Prostate Cancer: Understanding Out-of-Pocket Medication Costs – Daniel Joyce
Daniel Joyce discusses the financial impact of advanced prostate cancer treatments on patients. He presents research showing significant out-of-pocket costs for oral cancer therapies, particularly…